Page last updated: 2024-11-13
gsk1325756
Description
danirixin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 24780598 |
| CHEMBL ID | 3039531 |
| SCHEMBL ID | 1198688 |
| MeSH ID | M0585895 |
Synonyms (33)
| Synonym |
|---|
| CHEMBL3039531 |
| gsk1325756b |
| gsk-1325756b |
| gsk-1325756 |
| danirixin |
| 1-(4-chloro-2-hydroxy-3-(((3s)-piperidine-3-sulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea |
| 954126-98-8 |
| gsk1325756 |
| gsk 1325756 |
| unii-r318pgh5vp |
| danirixin [usan:inn] |
| r318pgh5vp , |
| n-(4-chloro-2-hydroxy-3-(3-piperidinylsulfonyl)phenyl)-n'-(3-fluoro-2-methylphenyl)urea |
| danirixin (usan/inn) |
| D10387 |
| (s)-1-(4-chloro-2-hydroxy-3-(piperidin-3-ylsulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea |
| danirixin [who-dd] |
| danirixin [usan] |
| danirixin [inn] |
| SCHEMBL1198688 |
| 1-[4-chloro-2-hydroxy-3-[(3s)-piperidin-3-yl]sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea |
| gtpl8500 |
| HY-19768 |
| CS-5465 |
| EX-A1178 |
| AKOS030527036 |
| mfcd27987922 |
| danirixin (gsk1325756) |
| DB11922 |
| Q27076980 |
| S6620 |
| urea, n-[4-chloro-2-hydroxy-3-[(3s)-3-piperidinylsulfonyl]phenyl]-n'-(3-fluoro-2-methylphenyl)- |
| AC-36168 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|
| " There was a 37% decrease in Cmax and a 16% decrease in AUC (0-∞) following administration of danirixin in the presence of food." | ( The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects.
Bloomer, JC; Carpenter, DC; Connolly, P; Cooray, H; Lazaar, AL; Miller, BE; Mistry, S; Smart, K; Tal-Singer, R, 2015) | 0.66 |
| " This manuscript outlines a nonclinical approach comprising multiple biopharmaceutical, in vitro and physiologically based pharmacokinetic model (PBPK) modelling studies to enable selection of an alternative salt form for danirixin (DNX, GSK1325756), a pharmaceutical agent being developed for chronic obstructive pulmonary disease (COPD)." | ( Identification and characterisation of a salt form of Danirixin with reduced pharmacokinetic variability in patient populations.
Ambery, C; Bloomer, JC; Connolly, P; Garden, H; Henley, N; Hodnett, N; Keel, S; Kreindler, JL; Lazaar, AL; Lloyd, RS; Matthews, W; Miller, BE; Yonchuk, J, 2017) | 0.64 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|
| " All subjects also received omeprazole 20 mg each morning beginning 4 days prior to the first treatment period and continuing through danirixin dosing in the final treatment period." | ( The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers.
Ambery, CL; Bloomer, JC; Connolly, P; Lazaar, AL; Miller, BE; Mistry, S; Sanderson, D; Shreeves, T; Smart, K; Smith, R, 2014) | 0.63 |
| " Dosed with normal/high fat food the selected formulation showed comparable exposure and a modest increase in DNX systemic PK was observed with PPI dependent on meal type." | ( Negative Food Effect of Danirixin: Use of PBPK Modelling to Explore the Effect of Formulation and Meal Type on Clinical PK.
Ambery, C; Bloomer, JC; Butler, JM; Charles, SJ; D'Amico, D; Donald, A; Hingle, MI; Lloyd, RS; Miller, B; Paul, A; Tal-Singer, R; Zhu, X, 2020) | 0.56 |
Protein Targets (2)
Inhibition Measurements
Biological Processes (17)
Molecular Functions (8)
Ceullar Components (9)
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 5 (41.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 16.71
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 16.71 (24.57) | | Research Supply Index | 3.04 (2.92) | | Research Growth Index | 4.57 (4.65) | | Search Engine Demand Index | 10.37 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 8 (66.67%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (33.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |